Abnormal Low Density Lipoprotein Receptor Localization and Function in AD

AD 中低密度脂蛋白受体定位和功能异常

基本信息

  • 批准号:
    8079327
  • 负责人:
  • 金额:
    $ 30.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We seek to elucidate the interactive roles that atherosclerosis and Abeta play in the pathogenesis of co-morbid Alzheimer's disease (AD) and vascular dementia. Although, most of the field's efforts have been focused on the role of LDL, ApoE and their receptors play in AD pathogenesis, we have obtained evidence that APP/Abeta alters the expression and localization of the LDLR, such that it becomes concentrated in single perinuclear aggregate, rather than sorting to the cell surface. Other experiments suggest that Abeta induces a general defect in the MT network that likely leads to the mis-localization of some, but not all membrane proteins, including the LDLR, potentially rendering it (them) less active. We therefore propose to Test the Hypotheses that 1. APP/Abeta affects LDLR expression and intracellular localization. 2. Abeta-induced LDLR mis-localization leads to LDLR functional deficits, hyperlipidemia and atherosclerosis. The proposed experiments are significant because they may allow us to conclude that one reason why atherosclerosis, especially in the brain so often accompanies AD is because it is promoted by LDLR functional deficits induced by Abeta. Furthermore, the differences in affinity/activation of the different isoforms of ApoE for LDLR may be made more acute when the LDLR is less active, thus accounting in part for the increased risk of AD imparted by ApoE4. These findings and conclusions form the foundation for a comprehensive series of experiments to test the above hypotheses and determine whether Abeta induces the mis-sorting and functional inactivity of other important neuronal and non-neuronal proteins in the AD, particularly, growth factor receptors and the insulin receptor.
描述(由申请人提供):我们试图阐明动脉粥样硬化和β在阿尔茨海默病(AD)和血管性痴呆共病发病机制中的相互作用。虽然,该领域的大部分努力都集中在LDL、ApoE及其受体在AD发病机制中的作用上,但我们已经获得了APP/Abeta改变LDLR的表达和定位的证据,使其集中在单个核周聚集体中,而不是分类到细胞表面。其他实验表明,Abeta诱导了MT网络的普遍缺陷,这可能导致一些(但不是所有)膜蛋白(包括LDLR)的错误定位,从而潜在地降低了它(它们)的活性。因此,我们建议检验以下假设:APP/ β影响LDLR的表达和细胞内定位。2. β诱导的LDLR错误定位导致LDLR功能缺陷、高脂血症和动脉粥样硬化。提出的实验意义重大,因为它们可能使我们得出结论,动脉粥样硬化,特别是大脑中动脉粥样硬化经常伴随AD的一个原因是,由β诱导的LDLR功能缺陷促进了动脉粥样硬化。此外,当LDLR活性较低时,ApoE不同亚型对LDLR的亲和力/激活差异可能会变得更加严重,从而部分解释了ApoE4导致AD风险增加的原因。这些发现和结论为一系列全面的实验奠定了基础,以验证上述假设,并确定Abeta是否诱导AD中其他重要的神经元和非神经元蛋白,特别是生长因子受体和胰岛素受体的错误分类和功能失活。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Huntington Potter其他文献

Huntington Potter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Huntington Potter', 18)}}的其他基金

GM-CSF/sargramostim treatment to improve cognition in Down syndrome
GM-CSF/沙格司亭治疗可改善唐氏综合症的认知能力
  • 批准号:
    10304446
  • 财政年份:
    2021
  • 资助金额:
    $ 30.34万
  • 项目类别:
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease
GM-CSF/沙格司亭治疗阿尔茨海默病的 II 期试验
  • 批准号:
    10335221
  • 财政年份:
    2021
  • 资助金额:
    $ 30.34万
  • 项目类别:
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease
GM-CSF/沙格司亭治疗阿尔茨海默病的 II 期试验
  • 批准号:
    10534753
  • 财政年份:
    2021
  • 资助金额:
    $ 30.34万
  • 项目类别:
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD
AD 中低密度脂蛋白受体定位和功能异常
  • 批准号:
    8634227
  • 财政年份:
    2011
  • 资助金额:
    $ 30.34万
  • 项目类别:
Neuronal dysfunction caused by Abeta inhibition of MT motors
Abeta 抑制 MT 马达引起的神经元功能障碍
  • 批准号:
    8626688
  • 财政年份:
    2011
  • 资助金额:
    $ 30.34万
  • 项目类别:
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD
AD 中低密度脂蛋白受体定位和功能异常
  • 批准号:
    8688124
  • 财政年份:
    2011
  • 资助金额:
    $ 30.34万
  • 项目类别:
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD
AD 中低密度脂蛋白受体定位和功能异常
  • 批准号:
    8878140
  • 财政年份:
    2011
  • 资助金额:
    $ 30.34万
  • 项目类别:
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD
AD 中低密度脂蛋白受体定位和功能异常
  • 批准号:
    8494500
  • 财政年份:
    2011
  • 资助金额:
    $ 30.34万
  • 项目类别:
Neuronal dysfunction caused by Abeta inhibition of MT motors
Abeta 抑制 MT 马达引起的神经元功能障碍
  • 批准号:
    8443416
  • 财政年份:
    2011
  • 资助金额:
    $ 30.34万
  • 项目类别:
Neuronal dysfunction caused by Abeta inhibition of MT motors
Abeta 抑制 MT 马达引起的神经元功能障碍
  • 批准号:
    8206069
  • 财政年份:
    2011
  • 资助金额:
    $ 30.34万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了